Generation Bio
GBIO
GBIO was delisted on the 6th of February, 2026.
97 hedge funds and large institutions have $1.25B invested in Generation Bio in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 39 increasing their positions, 22 reducing their positions, and 11 closing their positions.
82% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 11
77% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 22
10% more funds holding
Funds holding: 88 → 97 (+9)
0.31% more ownership
Funds ownership: 7.9% → 8.21% (+0.31%)
1% less capital invested
Capital invested by funds: $1.27B → $1.25B (-$19M)
100% less call options, than puts
Call options by funds: $3K | Put options by funds: $3.07M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCM
Yiheng Capital Management
San Francisco,
California
|
+$42.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.67M |
| 4 |
Morgan Stanley
New York
|
+$7.59M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$6.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$25.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$16.3M |
| 3 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$6.24M |
| 4 |
Goldman Sachs
New York
|
-$4.36M |
| 5 |
BlackRock
New York
|
-$1.89M |
GBIO Hedge Fund Activity: Q2 2021 in Review
97 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q2 2021, worth a combined $1.25B — down 1.5% from $1.27B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new GBIO positions and 11 closed out — a net gain of 9 holders — while 39 added to existing stakes and 22 trimmed.
The largest buyer was Yiheng Capital Management, opening a new position worth an estimated $42.4M. The largest seller was Deerfield Management, exiting entirely with an estimated $25.6M sold.
- 97 institutional investors held Generation Bio (GBIO) as of Q2 2021, up from 88 in Q1 2021.
- Funds reported $1.25B of Generation Bio stock for Q2 2021, down 1.5% quarter-over-quarter.
- 20 funds opened new Generation Bio positions in Q2 2021 and 11 closed out, a net change of +9 holders.
- The largest Generation Bio buyer in Q2 2021 was Yiheng Capital Management, an estimated $42.4M added.
- The largest Generation Bio seller in Q2 2021 was Deerfield Management, an estimated $25.6M sold.
Based on aggregated 13F filings for Q2 2021.